Gerresheimer (ETR:GXI) Trading 0.6% Higher - Should You Buy?

Key Points

• Shares rose 0.6% to €19.10 on Tuesday, with volume of ~254,120 shares—about an 80% increase versus the average daily volume.
• Balance-sheet and valuation mixed: liquidity is low (quick ratio 0.40, current ratio 0.98) and leverage very high (debt-to-equity 164.82), yet the stock shows a low P/E of 5.72 and P/E/G of 0.82 and is trading below its 50- and 200-day moving averages (€23.54 and €28.90).
• Core business: Gerresheimer manufactures medicine packaging and drug-delivery devices (prefillable syringes, vials, inhalers, autoinjectors) across its Plastics & Devices, Primary Packaging Glass and Advanced Technologies divisions.

Gerresheimer AG (ETR:GXI - ) shares were up 0.6% during trading on Tuesday . The stock traded as high as €19.10 and last traded at €19.10. Approximately 254,120 shares traded hands during trading, an increase of 80% from the average daily volume of 140,925 shares. The stock had previously closed at €18.99.

Gerresheimer Stock Performance

The company has a quick ratio of 0.40, a current ratio of 0.98 and a debt-to-equity ratio of 164.82. The company has a market cap of $653.92 million, a P/E ratio of 5.72, a P/E/G ratio of 0.82 and a beta of 0.57. The business has a fifty day simple moving average of €23.54 and a two-hundred day simple moving average of €28.90.

Gerresheimer Company Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.